Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effective and rapid sealing of coronary, aortic and atrial suture lines †

J. Skorpil, A. Paraforos, J. Mandak, WE. Cohn, T. Hajek, I. Friedrich,

. 2015 ; 20 (6) : 720-4; discussion 724. [pub] 20150324

Language English Country England, Great Britain

Document type Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16010406

OBJECTIVES: Cardiac surgical procedures carry a high risk of perioperative bleeding. Surgical sealants are often used to prevent suture line bleeding. PreveLeak™ is a surgical sealant composed of bovine serum albumin, a polyaldehyde cross-linker, and other components that forms a soft, flexible, water-tight, mechanical seal that is biocompatible and bioresorbable. METHODS: A prospective, multicentre study evaluated PreveLeak use in 44 subjects undergoing 63 cardiac procedures, primarily coronary artery bypass grafting (n = 23/63, 36.5%) and aortic valve replacement (n = 19/63, 30.2%). PreveLeak was applied to 127 suture lines and the time to sealing evaluated upon clamp release. The primary safety endpoint was the incidence of significant bleeding, infections, neurological deficits and immune/inflammatory allergic responses within 6 weeks post-treatment; subjects were followed for 3 months. RESULTS: Immediate sealing was achieved at all sites in 42 of 44 subjects (95.5%) and 125 of 127 treatment sites (98.4%). There were nine primary safety events: eight infections and one transient neurological deficit. Most adverse events were mild (n = 46/71, 64.8%) or moderate (n = 18/71, 25.4%) in severity. One adverse event (transient vasospasm) was considered possibly sealant-related. One death occurred due to a cardiac arrest. CONCLUSIONS: PreveLeak prevented bleeding at 98.4% of treated sites and was well tolerated; adverse events were consistent with those commonly observed in subjects undergoing surgical procedures. These results compared favourably with published studies of other sealants. The observed prevention of bleeding is clinically important in cardiac surgical patients. A randomized, comparative study is justified to further evaluate PreveLeak and confirm the findings from this study.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010406
003      
CZ-PrNML
005      
20160414105115.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/icvts/ivv061 $2 doi
024    7_
$a 10.1093/icvts/ivv061 $2 doi
035    __
$a (PubMed)25810290
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Skorpil, Jiri $u Department of Cardiac Surgery, University Hospital of Pilsen, Pilsen, Czech Republic skorpilj@fnplzen.cz.
245    10
$a Effective and rapid sealing of coronary, aortic and atrial suture lines † / $c J. Skorpil, A. Paraforos, J. Mandak, WE. Cohn, T. Hajek, I. Friedrich,
520    9_
$a OBJECTIVES: Cardiac surgical procedures carry a high risk of perioperative bleeding. Surgical sealants are often used to prevent suture line bleeding. PreveLeak™ is a surgical sealant composed of bovine serum albumin, a polyaldehyde cross-linker, and other components that forms a soft, flexible, water-tight, mechanical seal that is biocompatible and bioresorbable. METHODS: A prospective, multicentre study evaluated PreveLeak use in 44 subjects undergoing 63 cardiac procedures, primarily coronary artery bypass grafting (n = 23/63, 36.5%) and aortic valve replacement (n = 19/63, 30.2%). PreveLeak was applied to 127 suture lines and the time to sealing evaluated upon clamp release. The primary safety endpoint was the incidence of significant bleeding, infections, neurological deficits and immune/inflammatory allergic responses within 6 weeks post-treatment; subjects were followed for 3 months. RESULTS: Immediate sealing was achieved at all sites in 42 of 44 subjects (95.5%) and 125 of 127 treatment sites (98.4%). There were nine primary safety events: eight infections and one transient neurological deficit. Most adverse events were mild (n = 46/71, 64.8%) or moderate (n = 18/71, 25.4%) in severity. One adverse event (transient vasospasm) was considered possibly sealant-related. One death occurred due to a cardiac arrest. CONCLUSIONS: PreveLeak prevented bleeding at 98.4% of treated sites and was well tolerated; adverse events were consistent with those commonly observed in subjects undergoing surgical procedures. These results compared favourably with published studies of other sealants. The observed prevention of bleeding is clinically important in cardiac surgical patients. A randomized, comparative study is justified to further evaluate PreveLeak and confirm the findings from this study.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a aortální chlopeň $x chirurgie $7 D001021
650    12
$a biokompatibilní materiály $7 D001672
650    _2
$a krvácení při operaci $x prevence a kontrola $7 D016063
650    12
$a koronární bypass $x škodlivé účinky $x mortalita $7 D001026
650    _2
$a koronární vazospasmus $x etiologie $7 D003329
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční zástava $x etiologie $7 D006323
650    12
$a chirurgická náhrada chlopně $x škodlivé účinky $x mortalita $7 D019918
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pooperační krvácení $x prevence a kontrola $7 D019106
650    _2
$a prospektivní studie $7 D011446
650    _2
$a infekce chirurgické rány $x etiologie $7 D013530
650    12
$a šicí techniky $x škodlivé účinky $x mortalita $7 D013536
650    _2
$a časové faktory $7 D013997
650    _2
$a tkáňová adheziva $x škodlivé účinky $x terapeutické užití $7 D014014
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Česká republika $7 D018153
651    _2
$a Německo $7 D005858
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Paraforos, Alexandros $u Department of Cardiac Surgery, Hospital of the Brothers of Charity, Trier, Germany.
700    1_
$a Mandak, Jiri $u Department of Cardiac Surgery, University Hospital of Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Cohn, William E $u Department of Cardiopulmonary Transplantation and the Center for Cardiac Support, Texas Heart Institute, Houston, TX, USA.
700    1_
$a Hajek, Tomas $u Department of Cardiac Surgery, University Hospital of Pilsen, Pilsen, Czech Republic.
700    1_
$a Friedrich, Ivan $u Department of Cardiac Surgery, Hospital of the Brothers of Charity, Trier, Germany.
773    0_
$w MED00008612 $t Interactive cardiovascular and thoracic surgery $x 1569-9285 $g Roč. 20, č. 6 (2015), s. 720-4; discussion 724
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25810290 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160414105159 $b ABA008
999    __
$a ok $b bmc $g 1113835 $s 934774
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 20 $c 6 $d 720-4; discussion 724 $e 20150324 $i 1569-9285 $m Interactive cardiovascular and thoracic surgery $n Interact Cardiovasc Thorac Surg $x MED00008612
LZP    __
$a Pubmed-20160408

Find record

Citation metrics

Archiving options